nelfinavir has been researched along with Body Weight in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eichinger-Chapelon, A; Pfister, T | 1 |
| Aguiar, CV; Braga Neto, MB; Brito, GA; Guerrant, RL; Lima, AA; Maciel, JG; Oliveira, BM; Oriá, RB; Sevilleja, JE; Warren, CA | 1 |
| Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Geelen, SP; van Rossum, AM; Wolfs, TF | 1 |
| Aweeka, FT; Floren, LC; Hayashi, S; Jayewardene, A; Johnson, G; Krogstad, P; Nachman, S; Stanley, K; Wiznia, A | 1 |
| Doyle, ME; Ellis, KJ; Hardin, DS; Rice, J | 1 |
| Bressolle, F; Compagnucci, A; Faye, A; Giaquinto, C; Gibbs, D; Gomeni, R; Jacqz-Aigrain, E; Payen, S | 1 |
| Alvero, C; Fenton, T; Fletcher, CV; Saitoh, A; Spector, SA | 1 |
| Auleley, S; Duval, X; Hirt, D; Mentré, F; Rey, E; Salmon, D; Tran, A; Tréluyer, JM | 1 |
| Elmadfa, I; Jilma, B; Parschalk, B; Pernerstorfer-Schoen, H; Schindl, A; Schindler, K; Thoeny-Lampert, S; Tschachler, E; Wunderer, K | 1 |
| Elmadfa, I; Pernerstorfer-Schoen, H; Rieger, A; Schindler, K; Schneider, B | 1 |
| Croom, DK; Furfine, ES; Lenhard, JM; Reynolds, DJ; Spaltenstein, A; Weiel, JE | 1 |
| Baede-van Dijk, PA; Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Verweij-van Wissen, CP | 1 |
4 trial(s) available for nelfinavir and Body Weight
| Article | Year |
|---|---|
Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Antiretroviral Therapy, Highly Active; Biological Availability; Body Weight; Child; Child, Preschool; Dosage Forms; Drug Administration Schedule; HIV Protease Inhibitors; HIV-1; Humans; Infant; Nelfinavir; Nevirapine | 2003 |
Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Topics: Aging; Bayes Theorem; Body Weight; Chromatography, High Pressure Liquid; Didanosine; Drug Interactions; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Models, Biological; Nelfinavir; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Stavudine | 2005 |
Positive impact of protease inhibitors on body composition and energy expenditure in HIV-infected and AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Body Composition; Body Weight; Diet; Drug Therapy, Combination; Energy Intake; Energy Metabolism; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Nelfinavir; Weight Gain | 2000 |
Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aryl Hydrocarbon Hydroxylases; Body Weight; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Databases, Factual; Diarrhea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Omeprazole | 2001 |
8 other study(ies) available for nelfinavir and Body Weight
| Article | Year |
|---|---|
General 4-week toxicity study with EMS in the rat.
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Drug Contamination; Eating; Ethyl Methanesulfonate; Female; Genitalia; Hematologic Tests; Hemoglobins; HIV Protease Inhibitors; Male; Mutagens; Nelfinavir; Organ Size; Rats; Rats, Wistar; Risk Assessment; Specific Pathogen-Free Organisms; Toxicity Tests | 2009 |
Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.
Topics: Animals; Anti-Retroviral Agents; Apoptosis; Body Weight; Cell Membrane Permeability; Cell Proliferation; Didanosine; HIV Protease Inhibitors; Indinavir; Intestinal Absorption; Intestinal Mucosa; Male; Mice; Models, Animal; Necrosis; Nelfinavir; Reverse Transcriptase Inhibitors; Survival Rate; Water-Electrolyte Balance; Zidovudine | 2010 |
Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Topics: Adolescent; Body Surface Area; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Nelfinavir; Retrospective Studies; RNA, Viral | 2003 |
Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection.
Topics: Body Composition; Body Weight; Carbon Isotopes; CD4 Lymphocyte Count; Child; Child, Preschool; Clinical Trials as Topic; Drug Administration Schedule; Energy Metabolism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infusions, Intravenous; Leucine; Male; Muscle Proteins; Nelfinavir; Time Factors; Viral Load | 2004 |
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Topics: Adolescent; Age Factors; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Mass Index; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; DNA, Mitochondrial; DNA, Viral; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lipids; Longitudinal Studies; Mitochondria; Nelfinavir; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral | 2007 |
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Biotransformation; Body Weight; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Polymorphism, Genetic; Treatment Outcome; Viral Load | 2008 |
Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Basal Metabolism; Body Composition; Body Weight; Case-Control Studies; Cohort Studies; Didanosine; Energy Metabolism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Viremia | 1999 |
Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carbamates; Dietary Fats; Drug Interactions; Furans; HIV Protease Inhibitors; Indinavir; Injections, Subcutaneous; Insulin; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Saquinavir; Sulfonamides | 2000 |